Pediatric neurofibrosarcoma

Presented at the 33rd Annual Meeting of the American Pediatric Surgical Association, Phoenix, Arizona, May 19-23, 2002.
https://doi.org/10.1053/jpsu.2003.50105Get rights and content

Abstract

Background/Purpose: Neurofibrosarcoma is rare in children, and the natural history and prognostic factors are not well described. The authors present a 57-year review of their experience. Methods: The charts of children with neurofibrosarcoma were reviewed retrospectively. Statistical analysis was performed using the X2 and unpaired t tests. Results: From 1944 to 2001, 38 patients under the age of 21 were diagnosed with neurofibrosarcoma. Twenty-two were boys. The average age at diagnosis was 13.8 years (range, 3 to 19.9 years). Nineteen patients (50%) had neurofibromatosis. The tumor site was as follows: extremity, 19 patients; trunk, 9 patients; head and neck, 7 patients; and retroperitoneum, 3 patients. The average tumor size was 10 cm. The margins after resection were as follows: grossly positive, 9; microscopically positive, 5; negative, 21; and unknown, 3. Patients with positive margins had a 22% survival rate, whereas those with negative or unknown margins had a 34% survival rate. Thirty-two patients achieved a complete response, 2 a partial response, and 4 progressed while on therapy. Twenty-six patients relapsed after a complete response (11 local, 10 distant, 5 both). Of the 15 patients with a distant relapse, 73% (11) relapsed in the lung. Twelve (32%) patients survived with an average follow-up of 14 years (range, 0.3 to 28 years). Nine patients were treated with chemotherapy, 9 with radiation, and 9 with both chemotherapy and radiation. Outcome was not significantly affected by gender, presence of neurofibromatosis, site, margin, or use of adjuvant therapy. Conclusion: Neurofibrosarcoma remains a rare disease in children with insufficient contemporary numbers to assess efficacy of therapy. Prognosis remains poor with a high incidence of relapse, particularly in the lungs, suggesting that more aggressive therapies to control both local and distant relapses are needed. J Pediatr Surg 38:343-346. Copyright 2003, Elsevier Science (USA). All rights reserved.

Section snippets

Materials and methods

A comprehensive search of the patient files at MD Anderson Cancer Center was performed by requesting the charts of all patients under the age of 21 years with the diagnosis of neurogenic sarcoma, neurofibrosarcoma, malignant peripheral nerve sheath tumor, or malignant schwannoma. The charts then were evaluated to ensure that patients selected were diagnosed accurately. These charts were reviewed retrospectively for patient demographics, presentation, tumor location, size and grade, therapy

Results

From 1944 to 2001, 38 patients under the age of 21 years had neurofibrosarcoma diagnosed at MD Anderson Cancer Center. Twenty-two patients were boys. The average age at diagnosis was 13.8 years (range, 4 months to 19.9 years). Fifty percent of the children had (19) neurofibromatosis. The extremity was the most common site of the tumor with 19 tumors located either in the arm, leg, or thigh. The neurofibrosarcoma was located in the trunk in 8 patients, the head and neck region in 7 patients, and

Discussion

Neurofibrosarcoma remains a rare disease in children, constituting only 4% to 10% of all soft tissue sarcomas. Unlike other soft tissue sarcomas, which are of mesenchymal cell origin, neurofibrosarcomas are of neuroectodermal origin. Historically, this tumor has shown a significant variation in tumor morphology; however, immunohistochemical evaluation and electron microscopy may now aid in confirmation of diagnosis.5

Despite its rarity, neurofibrosarcoma should be included in the differential

References (18)

  • HI Neville et al.

    The role of surgery in children with neurofibromatosis

    J Pediatr Surg

    (2001)
  • PF Doorn et al.

    Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis

    Eur J Surg Oncol

    (1995)
  • JM DeCou et al.

    Malignant peripheral nerve sheath tumors: The St Jude Children's Research Hospital experience

    Ann Surg Oncol

    (1995)
  • BS Ducatman et al.

    Malignant peripheral nerve sheath tumors in childhood

    J Neuro Oncol

    (1984)
  • RB Raney et al.

    Results of multimodal therapy for children with neurogenic sarcoma

    Med Pediatr Oncol

    (1979)
  • B Raney et al.

    Treatment of children with neurogenic sarcoma: Experience at the Children's Hospital of Philadelphia, 1958-1984

    Cancer

    (1987)
  • JB Taxy et al.

    Electron microscopy in the diagnosis of malignant schwannoma

    Cancer

    (1981)
  • BS Ducatman et al.

    Postirradiation neurofibrosarcoma

    Cancer

    (1983)
  • JE Wanebo et al.

    Malignant peripheral nerve sheath tumors: A clinicopathologic study of 28 cases

    Cancer

    (1993)
There are more references available in the full text version of this article.

Cited by (36)

  • Pediatric soft tissue sarcomas

    2011, Seminars in Ultrasound, CT and MRI
    Citation Excerpt :

    Most patients with neurofibromatosis type I (NF1) have an 8%-13% risk of developing MPNSTs, but in those with an unusual mutation of the tumor suppressor gene, as many as 26% develop MPNSTs.112 Previous irradiation is also a risk factor.110 The lifetime risk of MPNST in the general population is 0.001%.113

  • Skeletal malignancies and related disorders

    2011, Textbook of Pediatric Rheumatology
View all citing articles on Scopus

Address reprint requests to Richard Andrassy, MD, 6431 Fannin MSB 4.020, Houston, TX 77030.

View full text